| 20176909 |
Gobin P, Lemaitre F, Marchand S, Couet W, Olivier JC: Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography tandem mass spectrometry (LC-MS/MS). Antimicrob Agents Chemother. 2010 Feb 22.
A rapid high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay was developed for routine quantification of colistins A and B and their prodrugs colistin methanesulfonate (CMS) A and B in human plasma and urine, using polymyxin B1 as internal standard (IS). CMS concentrations were determined indirectly by substracting colistin concentrations determined in biological samples from the whole colistin concentrations determined after sample treatment with sulfuric acid in order to hydrolize CMS into colistin. After extraction on SPE column, colistins were separated on an XBrigde (R) C18 column with isocratic elution (3.8 min runtime). The mobile phase was 0.1% (v/v) formic acid in acetonitrile : 0.1% (v/v) formic acid in water (20:80-v/v), run at a 0.2 mL/min flow rate. Ions were detected in the turbo ionspray positive and multiple reaction monitoring modes. Monitored ions (precursor [M+2H](2+) to product ions) were m/z 585.5/101.2 for colistin A, 578.5/101.2 for colistin B and 602.5/241.2 for IS. Pre-validation studies demonstrated CMS stability in biological samples and extracts, a key-point for reliable quantification of colistin and CMS. The assay was accurate and reproducible for quantification of colistins A and B and CMS A and B in plasma samples over concentration ranges appropriate for pharmacokinetic studies: 0.024 to 6.144 mug/mL, 0.015 to 3.856, 0.029 to 7.492 and 0.010 to 2.508 mug/mL, respectively. In urine samples, the assay was validated over the same concentration ranges for colistins and over 0.058 to 7.492 mug/mL and 0.020 to 2.508 mug/mL for CMS A and B respectively. |
1(0,0,0,1) |